Alternative venlafaxine kinetics in overdose

Journal of Clinical Pharmacy and Therapeutics

Volumn 27, Issue 6, 2002, Pages 465-467

  Langford, N J ^a,b   Martin, U ^b   Ruprah, M ^c   Ferner, R E ^a,b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CYP2D6; Metabolism; Overdose; Pharmacokinetics; Venlafaxine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; VENLAFAXINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; FEMALE; HUMAN;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; OVERDOSE; PYRIDINES;

EID: 18744380007     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2002.00438.x     Document Type: Article

References (13)

1. Henry JA. (1997) Toxicity of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 40-45.
2. Parker V, Pearg L, Maloney K, et al. (1990) Effect of age and sex on the pharmacokinetics of venlafaxine. Journal of Clinical Pharmacology, 30, 832.
3. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. Journal of Clinical Pharmacology, 32, 716-724.
4. Blythe D, Hackett LP. (1999) Cardiovascular and neurological toxicity of venlafaxine. Human and Experimental Toxicology, 18, 309-313.
5. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. British Journal of Clinical Pharmacology, 41, 149-156.
6. Vandel P, Haffen E, Vandel S, et al. (1999) Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. European Journal of Clinical Pharmacology, 55, 659-665.
7. Troy SM, Parker VD, Fruncilli RJ, Chiang ST. (1995) The pharmacokinetics of venlafaxine when given in a twice daily regimen. Journal of Clinical Pharmacology, 35, 404-409.
8. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST. (1995) Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction betweem venlafaxine and diazepam. Journal of Clinical Pharmacology, 35, 410-419.
9. Prichard L, Gillet G, Bonfils C, Domergue J, Thenot J-P, Maurel P. (1995) Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metabolism Dispos, 23, 1253-1262.
10. Elko CJ, Burgess JL, Roberteon WO. (1998) Zoplidem-associated hallucinations and serotonin reuptake inhibition: A possible reaction. Clinical Toxicology, 36, 195-203.
11. 2) sites on capsaicin-sensitive afferent neurones. British Journal of Pharmacology, 113, 268-274.
12. Bornheim LM, Lasker JM, Raucy JL. (1992) Human hepatic microsomal metabolism of Delta 1-tetra-hydrocannabinol. Drug Metabolism and Disposition, 20, 241-246.
13. 1 receptors in human ileum. British Journal of Pharmacology, 125, 1393-1395.